Capivasertib is an Orally Active Pan-AKT Kinase Inhibitor for Breast Cancer Research
On November 16, 2023, the Food and Drug Administration approved Capivasertib with Fulvestrant for adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or…